Table 1.
Study population by phase of study, country, and medication type
| Medication type | Phase 1: qualitative pilot survey | Phase 2: quantitative pilot survey | Phase 3: main survey | Final analysis samplea | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UK | US | Total | UK | US | Total | UK | US | Total | UK | US | Total | |
| Insulin pen | 3 | 2 | 5 | 19 | 13 | 32 | 103 | 115 | 218 | 122 | 128 | 250 |
| GLP-1 RA | 2 | 3 | 5 | 1 | 7 | 8 | 128 | 118 | 246 | 129 | 125 | 254 |
| Total | 5 | 5 | 10 | 20 | 20 | 40 | 231 | 233 | 464 | 251 | 253 | 504 |
UK United Kingdom, US United States, GLP-1 RA glucagon-like peptide 1 receptor agonist
aBecause no changes were made to the survey during or following phase 2, the phase 2 data were combined with phase 3 data for the final analysis sample